Use of [F-18] FLT for Imaging With Positron Emission Tomography (PET)

Who is this study for? Adult patients with Solid Tumors or Hematological Malignancies
What treatments are being studied? 3'-Deoxy-3'-18F Fluorothymidine
Status: Recruiting
Location: See location...
Intervention Type: Device
Study Type: Interventional
SUMMARY

RATIONALE: Diagnostic procedures, such as 3'-deoxy-3'-\[18F\] fluorothymidine (FLT) PET imaging, may help find and diagnose cancer. It may also help doctors predict a patient's response to treatment and help plan the best treatment. PURPOSE: This phase I trial is studying FLT PET imaging in patients with cancer.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 120
Healthy Volunteers: f
View:

∙ DISEASE CHARACTERISTICS:

• Meets one of the following criteria:

‣ Histologically confirmed solid tumor or hematologic malignancy

⁃ Awaiting biopsy or surgery for cancer evaluation of a mass detected on exam or standard imaging

∙ PATIENT CHARACTERISTICS:

• Able to lie still in the PET scanner

• Girth and weight must be suitable to enter the gantry

• Not pregnant or nursing

• Negative pregnancy test

• Fertile patients must use effective contraception

∙ PRIOR CONCURRENT THERAPY:

• Not specified

Locations
United States
Michigan
Barbara Ann Karmanos Cancer Institute
RECRUITING
Detroit
Time Frame
Start Date: 2009-09
Estimated Completion Date: 2028-05
Treatments
Experimental: 3'-deoxy-3'-[18F]fluorothymidine
The PET scan data collection is started immediately and is continued for 2 hours. This procedure will measure tumor growth within the body.
Sponsors
Leads: Barbara Ann Karmanos Cancer Institute
Collaborators: National Cancer Institute (NCI)

This content was sourced from clinicaltrials.gov

Similar Clinical Trials